Another biosimilar hopeful for Johnson & Johnson’s Stelara is taking steps to move to market as patent protections are set to end this year, this time in the form of a commercialization agreement between Sandoz and Samsung Bioepis that was announced today.
Sandoz and Samsung’s biosimilar…
Click here to view original post
